Eli Lilly (LLY) EVP Skovronsky vests 12,684 RSUs and updates share holdings

Rhea-AI Filing Summary

Eli Lilly EVP Daniel Skovronsky reported equity transactions on February 1, 2026. He exercised 12,684 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.

To cover related obligations, 5,641.249 common shares were withheld at a price of $1,037.15 per share. After these transactions, he directly holds 144,523.863 Eli Lilly common shares, with additional indirect holdings of 72,359 shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse's SLAT. He disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skovronsky Daniel

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CS&PO & Pres. LRL

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/01/2026		M		12,684	A	$0	150,165.112	D
Common Stock	02/01/2026		F		5,641.249	D	$1,037.15	144,523.863	D
Common Stock								72,359	I	By Trust(1)
Common Stock								547	I	By spouse(1)
Common Stock								2,710	I	By spouse's SLAT(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/01/2026		M			12,684	02/01/2026	02/01/2026	Common Stock	12,684	$0	0	D

Explanation of Responses:

1. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

2. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Remarks:

	/s/ Jonathan Groff for Daniel Skovronsky, pursuant to authorization on file	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eli Lilly (LLY) executive Daniel Skovronsky report in this Form 4?

Daniel Skovronsky reported exercising 12,684 restricted stock units into Eli Lilly common stock on February 1, 2026. A portion of the resulting shares was withheld to satisfy obligations, and his updated direct and indirect share holdings were disclosed.

How many Eli Lilly (LLY) shares does Daniel Skovronsky now hold directly?

Following the reported transactions, Daniel Skovronsky directly holds 144,523.863 shares of Eli Lilly common stock. This figure reflects both the vesting of 12,684 restricted stock units and the withholding of 5,641.249 shares at $1,037.15 per share.

What tax or obligation-related withholding occurred in this Eli Lilly (LLY) Form 4?

To cover related obligations, 5,641.249 Eli Lilly common shares were withheld at a price of $1,037.15 per share. This withholding followed the exercise of 12,684 restricted stock units that converted into the same number of common shares at an exercise price of $0.

What indirect Eli Lilly (LLY) share holdings are associated with Daniel Skovronsky?

Beyond directly held shares, indirect holdings include 72,359 shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse's SLAT. These positions are reported as indirect ownership interests related to Skovronsky’s overall economic exposure.

What does the beneficial ownership disclaimer mean in this Eli Lilly (LLY) filing?

The filing states that Daniel Skovronsky disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest. This means he reports these holdings but does not claim full ownership beyond his direct economic stake in the securities.

What are the restricted stock units reported by Eli Lilly (LLY) executive Daniel Skovronsky?

The filing notes that each restricted stock unit represents a contingent right to receive one share of Eli Lilly common stock. On February 1, 2026, 12,684 restricted stock units were converted into an equal number of common shares at an exercise price of $0.